Tonix Pharmaceuticals Holding Corp. (TNXP) on Tuesday said it received official minutes from the pre-IND meeting with FDA to develop TNX-102 SL as a potential treatment for Long COVID Syndrome.
Based on the minutes, the company plans to submit the investigational new drug application in the fourth quarter of 2021 for a Phase 2 study of TNX-102 SL in a subset of Long COVID patients whose symptoms overlap with fibromyalgia.
TNX-102 SL, a patented sublingual tablet formulation of cyclobenzaprine hydrochloride is in mid-Phase 3 development for the treatment of fibromyalgia.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.